Epilepsy and paroxysmal conditions

Advanced search


Full Text:


Pharmacotherapy of epilepsy requires deep knowledge  of anti-epileptic drugs (AEDs), including the following issues: spectrum of therapeutic efficacy and therapeutic strength, adverse effects (especially severe and life-threatening adverse reactions); specific features of pharmacokinetics,  pharmacodynamics, and drug interactions; titration rate, the need for laboratory tests  during treatment,  pharmacoeconomic components.  The main properties  of antiepileptic drugs  are defined by their mechanisms of action. Today, particular attention is paid to the drugs with broad spectrum  activity, which give an ability to use them in patients with so-called undifferentiated epilepsies. In this article, the authors describe their own experience in optimization of antiepileptic therapy in a group of 141 patients with various forms of epilepsy. This new optimized  strategy implies inclusion of modern  broad spectrum  AEDs in treatment  schemes along with the reduction  in use  of narrow spectrum  drugs.  Moreover, polytherapy  was  used  in most  of the cases  after treatment regimen correction. All the measures  allowed to achieve remission  in about half of the patients with epilepsy earlier considered as incurable.

About the Authors

K. V. Voronkova
N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

Voronkova  Kira Vladimirovna  – MD, PhD, professor  at Department  of Neurology.

1 Ostrovityanova St., Moscow, 117997

G. S. Golosnaya
City Clinical Hospital No 13
Russian Federation

Golosnaya Galina Stanislavovna – MD, PhD, associate  professor,  neurologist  at neonatal intensive care unit of CClH No  13  (Department   of  Obstetrics   No  1).

3  Sharikopodshipnikovskaya   St.,  Moscow, 115280

I. D. Lemeshko
I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation

Lemeshko  Irirna  Dmitrievna – MD, doctor  of functional  diagnostics,  neurologist,  epileptologist  at  University Children’s Hospital of I. M. Sechenov First MSMU.

19/1 Bolshaya Pirogovskaya St., Moscow, 119435

A. S. Petrukhin
N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

Petrukhin  Andrey Sergeevich  – MD, PhD, professor  at Department  of Neurology, Neurosurgery  and Medical Genetics of N. I. Pirogov  RNRMU.

Ostrovityanova  St.,  Moscow, 117997


1. Karlov V. A. Epilepsy in children and adult women and men: a manual for physicians [Epilepsiya u detei i vzroslykh zhenshchin i muzhchin: rukovodstvo dlya vrachei (in Russian)]. Moscow. 2010; 718 p.

2. Brodie M. Do we need any more new antiepileptic drugs? Epilepsy Res. 2001; 45: 3-6.

3. Kwan P., Brodie M. J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000; 341: 314-9.

4. Panayiotopoulos C. P. A Clinical Guide to Epileptic Syndromes and their Treatment. Springer. 2010; 654 P.

5. Mikhailov V. A. Topical issues of epileptology: stigma, quality of life and rehabilitation of patients. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 2 (3): 39-44.

6. Kwan P., Brodie M. J. Effectiveness of first antiepileptic drug. Epilepsia. 2001; 42: 1255-60.

7. Sazgar M., Bourgeois B. F. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol. 2005; 33 (4): 227-34.

8. Perucca E. et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998; 39 (1): 5-17.

9. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev. 2000; 22 (2): 75-80.

10. Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic disorders. 2002; 3: 217-225.

11. Benbadis S. R. The management of idiopathic generalized epilepsies. Acta Neurologica Scandinavica. 2005; 112: 63-67.

12. Vaz-Carneiro A. et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia. 2011; 52 (7): 1528-1167.

13. Voronkova K. V., Petrukhin A. S., Pylaeva O. A., Kholin A. S. Rational antiepileptic pharmacology. A guide for physicians [Ratsional’naya antiepilepticheskaya farmakologiya. Rukovodstvo dlya vrachei in Russian)]. Moscow. 2008; 192 p.

14. Brodie M. J., Johnson F. N. Carbamazepine in the treatment of seizure disorders: efficacy, pharmacokinetics and adverse event profile. Rev. Contemp. Pharmacother. 1997; 8: 87-122.

15. Kramer G. et al. Experience of generic drugs use in patients with epilepsy: electronic interview with the members of the German, Austrian and Swiss branches of the International League against epilepsy [Opyt primeneniya dzhenericheskikh preparatov u patsientov s epilepsiei: elektronnoe interv’yu chlenov nemetskogo, avstriiskogo i shveitsarskogo otdelenii Mezhdunarodnoi ligi po bor’be s epilepsiei. Epilepsia (in Russian)]. 2007; 48 (3): 609-611.


For citations:

Voronkova K.V., Golosnaya G.S., Lemeshko I.D., Petrukhin A.S. ADVANTAGES OF BROAD SPECTRUM ANTIEPILEPTIC DRUGS IN TREATMENT OF EPILEPSY. Epilepsy and paroxysmal conditions. 2017;9(1):79-85. (In Russ.)

Views: 1875

ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)